KR102770090B1 - 다환성 피리돈 유도체 - Google Patents
다환성 피리돈 유도체 Download PDFInfo
- Publication number
- KR102770090B1 KR102770090B1 KR1020207037581A KR20207037581A KR102770090B1 KR 102770090 B1 KR102770090 B1 KR 102770090B1 KR 1020207037581 A KR1020207037581 A KR 1020207037581A KR 20207037581 A KR20207037581 A KR 20207037581A KR 102770090 B1 KR102770090 B1 KR 102770090B1
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- compound
- substituent group
- unsubstituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2018-104160 | 2018-05-31 | ||
| JP2018104160 | 2018-05-31 | ||
| PCT/JP2019/021445 WO2019230857A1 (ja) | 2018-05-31 | 2019-05-30 | 多環性ピリドン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210018324A KR20210018324A (ko) | 2021-02-17 |
| KR102770090B1 true KR102770090B1 (ko) | 2025-02-18 |
Family
ID=68698906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207037581A Active KR102770090B1 (ko) | 2018-05-31 | 2019-05-30 | 다환성 피리돈 유도체 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11453669B2 (https=) |
| EP (1) | EP3805221A4 (https=) |
| JP (1) | JP7353707B2 (https=) |
| KR (1) | KR102770090B1 (https=) |
| CN (1) | CN112533922B (https=) |
| AU (1) | AU2019277547B2 (https=) |
| BR (1) | BR112020024098A2 (https=) |
| CA (1) | CA3101950A1 (https=) |
| CL (1) | CL2020002987A1 (https=) |
| CO (1) | CO2020014296A2 (https=) |
| CR (1) | CR20200645A (https=) |
| DO (1) | DOP2020000222A (https=) |
| EA (1) | EA202092923A1 (https=) |
| IL (1) | IL279050B2 (https=) |
| MA (1) | MA52802A (https=) |
| MX (1) | MX2020012185A (https=) |
| MY (1) | MY203593A (https=) |
| PE (1) | PE20201414A1 (https=) |
| PH (1) | PH12020551999A1 (https=) |
| SG (1) | SG11202011386QA (https=) |
| WO (1) | WO2019230857A1 (https=) |
| ZA (1) | ZA202007568B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4257137A3 (en) | 2018-05-31 | 2023-11-01 | Shionogi & Co., Ltd | Polycyclic carbamoylpyridone derivatives for the treatment of hiv |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2021107065A1 (ja) * | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
| EP4066839A4 (en) * | 2019-11-28 | 2023-12-27 | Shionogi & Co., Ltd | PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS |
| JP2021091671A (ja) * | 2019-11-28 | 2021-06-17 | 塩野義製薬株式会社 | 多環性ピリドン誘導体を含有する医薬組成物 |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| JP7407976B2 (ja) * | 2020-05-21 | 2024-01-04 | シーセン ファーマシューティカル カンパニー リミテッド | 縮合環誘導体及びその薬学的用途 |
| US20240018145A1 (en) * | 2020-07-27 | 2024-01-18 | Merck Sharp & Dohme Llc | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| EP4384178A4 (en) * | 2021-08-11 | 2025-07-02 | Merck Sharp & Dohme Llc | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLUENZA |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014099586A1 (en) * | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| WO2015089847A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| NZ540729A (en) | 2002-12-27 | 2008-03-28 | Angeletti P Ist Richerche Bio | Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
| KR101363875B1 (ko) | 2005-04-28 | 2014-02-21 | 시오노기세야쿠 가부시키가이샤 | Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체 |
| MX2008005137A (es) | 2005-10-27 | 2008-09-29 | Shionogi & Co | Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa. |
| CA2789457A1 (en) | 2010-02-26 | 2011-09-01 | Susumu Miyazaki | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| US9216995B2 (en) | 2010-04-12 | 2015-12-22 | Shionogi & Co., Ltd. | Pyridone derivative having integrase inhibitory activity |
| RU2014113230A (ru) * | 2011-10-12 | 2015-11-20 | Шионоги Энд Ко., Лтд. | Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| PE20151063A1 (es) | 2012-12-27 | 2015-08-03 | Japan Tobacco Inc | DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH |
| RS56701B1 (sr) | 2013-05-17 | 2018-03-30 | Merck Sharp & Dohme | Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze |
| EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| WO2014200080A1 (ja) | 2013-06-14 | 2014-12-18 | ヤンマー株式会社 | 予測装置、予測方法及びコンピュータプログラム |
| NO2865735T3 (https=) | 2013-07-12 | 2018-07-21 | ||
| ES2859102T3 (es) | 2013-07-12 | 2021-10-01 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| UA117499C2 (uk) | 2013-09-27 | 2018-08-10 | Мерк Шарп Енд Доум Корп. | Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл |
| WO2015199167A1 (ja) | 2014-06-25 | 2015-12-30 | 日本たばこ産業株式会社 | 置換されたスピロピリド［１，２－ａ］ピラジン誘導体の製造方法および中間体 |
| JPWO2016027879A1 (ja) | 2014-08-22 | 2017-06-01 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| WO2016090545A1 (en) | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
| US10150780B2 (en) | 2014-12-09 | 2018-12-11 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as HIV integrase inhibitors |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| WO2016154527A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
| KR20190057158A (ko) | 2015-04-02 | 2019-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| US10624912B2 (en) | 2015-11-17 | 2020-04-21 | Merck Sharp & Dohme Corp. | Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors |
| US10548910B2 (en) | 2015-11-17 | 2020-02-04 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CA3042314A1 (en) | 2016-12-02 | 2018-06-07 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| EP3752144B1 (en) | 2018-02-15 | 2022-12-28 | Merck Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| KR20210005139A (ko) | 2018-04-27 | 2021-01-13 | 머크 샤프 앤드 돔 코포레이션 | Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물 |
| CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| EP3801543B1 (en) | 2018-06-05 | 2024-09-11 | Merck Sharp & Dohme LLC | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
-
2019
- 2019-05-30 MA MA052802A patent/MA52802A/fr unknown
- 2019-05-30 IL IL279050A patent/IL279050B2/en unknown
- 2019-05-30 MX MX2020012185A patent/MX2020012185A/es unknown
- 2019-05-30 EA EA202092923A patent/EA202092923A1/ru unknown
- 2019-05-30 CN CN201980050400.4A patent/CN112533922B/zh active Active
- 2019-05-30 KR KR1020207037581A patent/KR102770090B1/ko active Active
- 2019-05-30 JP JP2020522576A patent/JP7353707B2/ja active Active
- 2019-05-30 SG SG11202011386QA patent/SG11202011386QA/en unknown
- 2019-05-30 EP EP19812190.7A patent/EP3805221A4/en active Pending
- 2019-05-30 WO PCT/JP2019/021445 patent/WO2019230857A1/ja not_active Ceased
- 2019-05-30 PE PE2020001864A patent/PE20201414A1/es unknown
- 2019-05-30 BR BR112020024098-2A patent/BR112020024098A2/pt active IP Right Grant
- 2019-05-30 CA CA3101950A patent/CA3101950A1/en active Pending
- 2019-05-30 CR CR20200645A patent/CR20200645A/es unknown
- 2019-05-30 MY MYPI2020006047A patent/MY203593A/en unknown
- 2019-05-30 AU AU2019277547A patent/AU2019277547B2/en active Active
- 2019-05-30 US US17/058,260 patent/US11453669B2/en active Active
-
2020
- 2020-11-17 CL CL2020002987A patent/CL2020002987A1/es unknown
- 2020-11-18 CO CONC2020/0014296A patent/CO2020014296A2/es unknown
- 2020-11-20 PH PH12020551999A patent/PH12020551999A1/en unknown
- 2020-11-27 DO DO2020000222A patent/DOP2020000222A/es unknown
- 2020-12-04 ZA ZA2020/07568A patent/ZA202007568B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014099586A1 (en) * | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| WO2015089847A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EA202092923A1 (ru) | 2021-04-09 |
| ZA202007568B (en) | 2022-04-28 |
| IL279050B1 (en) | 2024-08-01 |
| US20210155622A1 (en) | 2021-05-27 |
| IL279050A (en) | 2021-01-31 |
| EP3805221A1 (en) | 2021-04-14 |
| CN112533922B (zh) | 2024-03-22 |
| AU2019277547A1 (en) | 2021-01-14 |
| US11453669B2 (en) | 2022-09-27 |
| CO2020014296A2 (es) | 2020-12-21 |
| DOP2020000222A (es) | 2021-03-15 |
| JPWO2019230857A1 (ja) | 2021-06-24 |
| CN112533922A (zh) | 2021-03-19 |
| SG11202011386QA (en) | 2020-12-30 |
| AU2019277547B2 (en) | 2024-10-10 |
| MA52802A (fr) | 2021-04-14 |
| BR112020024098A2 (pt) | 2021-02-17 |
| MY203593A (en) | 2024-07-05 |
| EP3805221A4 (en) | 2022-01-05 |
| IL279050B2 (en) | 2024-12-01 |
| JP7353707B2 (ja) | 2023-10-02 |
| MX2020012185A (es) | 2021-01-29 |
| PH12020551999A1 (en) | 2021-09-27 |
| CR20200645A (es) | 2021-02-05 |
| KR20210018324A (ko) | 2021-02-17 |
| CL2020002987A1 (es) | 2021-04-16 |
| CA3101950A1 (en) | 2019-12-05 |
| PE20201414A1 (es) | 2020-12-07 |
| WO2019230857A1 (ja) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102770090B1 (ko) | 다환성 피리돈 유도체 | |
| KR102741390B1 (ko) | 다환성 카바모일피리돈 유도체 | |
| KR102612176B1 (ko) | Mgat2 저해 활성을 갖는 축합환 유도체 | |
| JP7776335B2 (ja) | 多環性ピリドピラジン誘導体 | |
| JP2025134871A (ja) | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 | |
| JP2023182723A (ja) | 多環性カルバモイルピリドン誘導体を含有する医薬組成物 | |
| JP2021091671A (ja) | 多環性ピリドン誘導体を含有する医薬組成物 | |
| HK40043566A (en) | Polycyclic pyridone derivative | |
| EA042593B1 (ru) | Полициклическое производное пиридона, полезное для лечения вич-инфекции, его фармацевтическая композиция и применение | |
| EA047250B1 (ru) | Полициклическое производное карбамоилпиридона | |
| EA053268B1 (ru) | Полициклическое производное карбамоилпиридона | |
| HK40093123A (en) | Polycyclic carbamoylpyridone derivatives for the treatment of hiv | |
| BR122025006471A2 (pt) | Derivado de carbamoilpiridona policíclica e composição farmacêutica compreendendo o mesmo | |
| TW202003517A (zh) | 多環性吡啶并三𠯤衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201228 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220427 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240309 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241115 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250214 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250214 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |